IGHV mutational status
Whether the leukaemia's antibody gene has been 'edited' by the immune system. Unmutated means faster-growing CLL and a bigger benefit from targeted drugs over chemotherapy.
IGHV genes with <2% deviation from germline are 'unmutated' (~40-50% of CLL) and predict shorter time to treatment and poor response to chemoimmunotherapy (FCR). BTK inhibitors and venetoclax combinations largely erase the difference for progression, and IGHV status is a stratification factor in every modern CLL trial (CLL13, AMPLIFY). Mutated-IGHV patients still achieve the longest remissions after fixed-duration therapy.
Pages like this
not linked directly; found by shared links- PairingVenetoclax + obinutuzumab (12 months)
Shares CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.
- Termdel(17p) / TP53 aberration in CLL
Shares AMPLIFY, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.
- PersonMichael Hallek
Shares CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.
- ProductObinutuzumab
Shares AMPLIFY, CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.
- TrialCAPTIVATE
Shares MRD-guided treatment duration in CLL, Chronic lymphocytic leukaemia.
- Key paperAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients
Shares AMPLIFY, CLL13 / GAIA, Chronic lymphocytic leukaemia.
- TrialCELESTIAL-TNCLL
Shares MRD-guided treatment duration in CLL, Chronic lymphocytic leukaemia.
- ProductAcalabrutinib
Shares AMPLIFY, Waldenström macroglobulinaemia, Chronic lymphocytic leukaemia.